PubMed Health⌕ Search

Biomedical subjects

C Engelking

Publications and source records attributed to C Engelking.

At least 19 recordsLinked to original sources

Management of cancer treatment-related diarrhea. Issues and therapeutic strategies.

The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood, but histopathologic evidence points to a multifactorial process that causes an absorptive and secretory imbalance in the small bowel. Cancer treatment-related diarrhea could be life-threatening, yet assessment and treatment are not currently standardized. Several clinicians participated in a closed roundtable meeting to review the mechanisms of chemotherapy-induced diarrhea (CID) and GVHD-induced diarrhea, management issues in cancer treatment-induced diarrhea, and pharmacologic approaches to treatment. The meeting produced a proposal for new treatment guidelines and an algorithm, which include the use of octreotide for the management of CID- and GVHD-induced diarrhea. The development of diarrhea assessment guidelines that expand on the current National Cancer Institute criteria and allow for better patient management was also proposed.

Antineoplastic Agents↗

Recommended guidelines for the treatment of chemotherapy-induced diarrhea.

PURPOSE: Management of chemotherapy-induced diarrhea (CID) has customarily involved symptomatic treatment with opioids in conjunction with supportive care. Alternatively, patients refractory to conventional therapy have been given octreotide, a somatostatin analogue. Although this agent has been effective against CID, no widely accepted treatment guidelines that incorporate its use currently exist. An expert multidisciplinary panel was convened to formulate clinical practice guidelines for the treatment of CID. METHODS: The panel reviewed clinical data on the management of CID reported in the literature and analyzed currently available tools used to assess CID. Expert consensus was applied when published data were insufficient. Panel members also considered the effect of CID on quality of life and the cost-effectiveness and efficacy of different pharmacologic approaches. Effective resolution of CID and decreases in the need for supportive care or hospitalization were considered to be primary goals in the formulation of the guidelines. RESULTS: The panel formulated suggested practice guidelines for the management of CID that detail recommendations for the assessment and evaluation of diarrhea and the sequence and duration of administration of specific pharmacologic agents. CONCLUSION: The consensus of the panel was that standardized assessment and management of diarrhea is required to effectively control CID. The panel agreed that further data from a National Cancer Institute (NCI)-sponsored intergroup trial is required to determine the optimal dosage of octreotide and its cost in the treatment of cancer. The panel also agreed that further clinical research is warranted to address significant questions about the most effective way to assess and treat CID.

Antineoplastic Agents↗

Cancer-related diarrhea: selected findings of a national survey of oncology nurse experiences.

PURPOSE/OBJECTIVES: To describe oncology nurse experiences with disease- and treatment-related diarrhea in patients with cancer, including assessment methods and pharmacologic/supportive care. DESIGN: Descriptive. SAMPLE/SETTING: 1,288 (26%) of 5,000 randomly selected Oncology Nursing Society members employed full-time in adult clinical settings in the United States. METHODS: Mailed survey with scannable booklets. MAIN RESEARCH VARIABLES: Nurse perceptions of disease and treatment-related issues associated with diarrhea in patients with cancer, along with currently used assessment criteria and nursing care. FINDINGS: Nurses in this sample routinely encounter diarrhea in their patients with cancer. They commonly assess/document diarrhea by noting its presence or absence, with a minority of nurses using a rating tool. When indicated, most nurses prepare patients for probable diarrhea. This preparation includes both verbal and written instructions about diet, skin care, drug therapy, and treatment of severe diarrhea. Nurses report that primary drug therapy for diarrhea consists of over-the-counter agents. Supportive care consists of fluid/electrolyte replacement, skin care and diet modifications, and also bowel rest and parenteral nutrition for severe diarrhea. For these nurses, the most important factors influencing choice of management strategies are symptom relief and physician and patient preference. CONCLUSIONS: Although the majority of nurses in this study report providing anticipatory guidance, patient education, and supportive diarrhea management, they are not assessing diarrhea systematically. They report common use of nonprescription medications, with pharmacologic interventions varying with severity of diarrhea. IMPLICATIONS FOR NURSING PRACTICE: Targeted education is needed to help nurses implement systematic assessment and documentation. Efficacy of diarrhea-management strategies and protocols must be tested-specifically, optimal timing and types of skin care, dietary changes, and bowel rest.

Adult↗

Genetics in cancer care: confronting a Pandora's Box of dilemmas.

PURPOSE/OBJECTIVES: To provide an overview of sociopolitical, bioethical, and psychological issues emerging from the application of genetic technologies in cancer care in the United States and to provoke oncology nurses to consider the impact that advances in genetics may have on their practice. DATA SOURCES: Published professional articles, tests, and proceedings as well as government and lay publications. DATA SYNTHESIS: This article reviews underlying sociopolitical issues and forecasts bioethical dilemmas and psychological responses likely to emerge from expanding genetic screening and treatment options in oncology. The sociopolitical issues revolve around individual rights, the role of government, and the influence of religious dogma and public perception. The bioethical dilemmas fall within a framework of five scenarios, and a range of psychological responses are described. CONCLUSIONS: Significant changes will occur in cancer care as a result of advances in genetic technology. These changes will be accompanied by a new set of dilemmas in clinical practice and by as yet undescribed psychological responses. In addition to building a knowledge base relevant to these new technologies, oncology nurses must anticipate the new dilemmas and be prepared to manage the emotional responses of their patients. NURSING IMPLICATIONS: Nurse are in a strategic position to make significant contributions to the genetics data base by designing and conducting research to describe the ethical dilemmas and patient/family responses engendered as genetic science is integrated into cancer care.

Bioethics↗

The human genome exposed: a glimpse of promise, predicament, and impact on practice.

PURPOSE/OBJECTIVES: To review basic gene biology, discuss current genetic advances, and project the potential impact of these advances on oncology nursing practice. DATA SOURCES: Published professional articles, tests, proceedings, governmental and lay publications. DATA SYNTHESIS: The Human Genome Project seeks to better describe the human complement of genes, which may hold the key to further defining the mechanism of carcinogenesis. The identification of genetic defects responsible for cancer will facilitate development of both preventive and therapeutic antitumor strategies. CONCLUSIONS: The data base emerging from genetic research will result in both promise and predicaments. The promise relates to the discovery of genetic abnormalities that can be used to predict risk for cancer or serve as targets for therapeutic intervention. The predicaments involve the psychosocial, ethical, and legal implications of revealing an individual's genetic profile without knowing the ultimate ramifications of that information. IMPLICATIONS FOR NURSING PRACTICE: Nurses will be at the forefront of these advances as they describe the effects of genetic advances on the public and on individuals and create innovative strategies to manage negative effects. To take advantage of opportunities presented by the genetic revolution, nurses must develop a knowledge base about gene biology and its relationship to cancer.

Chromosomes↗

Cancer in the elderly: the forgotten priority.

In 1992, the American Oncology Nursing Society produced a state-of-the-art document, recognizing the fact that cancer is primarily a disease of ageing and addressing the specific needs of elderly cancer patients. As 1993 has been dubbed the 'Year of the Elderly', European oncology nurses should also be establishing a framework to meet the cancer-specific needs of the elderly.

Aged↗

Propantheline prevention of mucositis from etoposide.

Mucosal toxicity is dose limiting for etoposide. This may be related to the direct effects of etoposide on the mucosa. Twelve patients receiving etoposide 1800 mg/m2 as part of a myeloablative pre-transplant regimen were randomized to receive propantheline 30 mg or placebo orally every 6 h for six doses. Mucositis was less frequent (2 of 6 vs 5 of 6) and less severe (p = 0.05) in the propantheline arm. There were no differences in tumor response or survival between the two groups. Propantheline is an anticholinergic that causes xerostomia by decreasing salivation. Propantheline may reduce the salivary excretion of etoposide and could reduce its toxic effects on the mucosa. Propantheline is effective in reducing the incidence and severity of mucositis in patients receiving high-dose etoposide.

Adult↗

Clinical trials: impact evaluation and implementation considerations.

It is commonplace for oncology nurses to care for patients entered on clinical trials. However, clinical research can impose a significant impact on the resources of sponsoring institutions or agencies, especially in today's environment of cost containment. Thus, institutions and nurses are increasingly involved in systematic resource impact evaluations to determine their commitment to cancer clinical trials. It is important for nursing to evaluate the impact of proposed clinical research and define the parameters for the participation of nursing service.

Clinical Protocols↗

Facilitating clinical trials. The expanding role of the nurse.

Clinical trials are becoming increasingly difficult to carry out in the face of a changing health care delivery system. The reluctance of third party payers to reimburse for experimental therapy and the growing practice of providers to limit resources allocated for the care of cancer patients undergoing such therapies seriously curtail the ability of investigators to test new cancer treatments clinically. In addition, certain beliefs, attitudes, and perceptions held by the public may interfere with patient case accrual. Nurses can help facilitate both accrual to and conduct of clinical research. This article addresses selected consumer- and provider-centered factors that inhibit clinical research. The expanding role of the nurse in the areas of public education, informed consent, direct care, and collaborative research is also described.

Attitude to Health↗

High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease.

Twenty three patients with Hodgkin's disease were treated with BCNU (carmustine), etoposide, and cyclophosphamide at doses of 450-600 mg/m2, 1500-2000 mg/m2, and 120 mg/kg respectively. Bone marrow refrigerated at 4 degrees C for 2-5 days or cryopreserved at -80 degrees C was used to reconstitute bone marrow function. The median age was 28 (range 16-48), and the median Karnofsky performance status was 70. Nineteen patients had progressive disease while on chemotherapy. The median number of prior regimens was three (1-7), and the median number of prior chemotherapy drugs was 10 (range 4-12). Ten patients had received at least two of the drugs used in this study and four had had all three. Indicator lesions included lung (10), peripheral lymph nodes (9), retroperitoneal nodes (8), liver (3), and chest wall masses (2). Ten patients achieved a complete remission (43.5%; 95% confidence limits 23-64%), and five patients had a partial remission (21.7%; 95% confidence limits 5-39%). The median duration of complete remission was 6 months (range 2-13+ months). Responses were shorter in duration for patients with primary refractory disease. Liver function abnormalities were noted in nine (39%) cases. Post transplant, the recovery time was 18 days (range 11-43) for WBC and 24 days (11-77) for platelets. Two patients died of septic episodes while neutropenic. The median number of RBC units used was seven (range 1-45). Ten patients had evidence of pulmonary dysfunction. In seven patients there was symptomatic improvement with steroid therapy, but three patients who were not treated with steroids died as a result of interstitial pneumonia. Future programs should consider bone marrow transplantation in patients with Hodgkin's disease earlier in the course of disease, at the time of minimal residual disease, and employ newer, potentially less toxic drugs.

Adolescent↗